Human Dendritic Cell (hDC) model
Dendritic cells are considered the most potent antigen presenting cells of the immune system and are responsible for activation of the adaptive immune system in response to infections. Dendritic cells are key regulators of the immune system in immunological disorders such as autoimmune and allergic diseases and are thus promising targets for treatment of these disorders.
Bioneer A/S offers screening of compounds in the hDC Model based upon human dendritic cells that can predict immune stimulating effects of added compounds. The hDC Model is based upon human myeloid dendritic cells differentiated from monocytes derived from healthy human donors.
This validated hDC Model is useful in determining the general immune stimulatory effect of a given compound, microorganism or probiotic strain.
By subjecting the hDC Model to our proprietary inflammatory cocktails, screening for anti-inflammatory effects of specific compounds is made possible. These cocktails are selected based on the response rates in dendritic cells obtained from multiple different human donors. The predictive power of the hDC Model has been validated using known anti-inflammatory drugs and read-outs including secretion of pro-inflammatory cytokines like e.g. IL12 and TNF-alpha. The cocktails are potent stimulators of DC-maturation and T-cell responses using MLR. Potential anti-inflammatory drug candidates or probiotics are tested for the ability to suppress the maturation of dendritic cells into disease like inflammatory dendritic cells.
In the predictive human dendritic cell models, Bioneer A/S offers assessment of dendritic cell activation by a number of biological end-points:
• Cytokine and Chemokine readout (e.g. IL6, 10, 12, 23, TNF)
• FACS analyses of maturation markers (e.g. CD40, 80, 86, MHC II)
• T-cell activation
• Intracellular markers of inflammation (e.g. COX2, iNOS, cytokines)
The predictive human DC models are suitable for screening of a limited number of drug candidates or probiotic strains, and in situations where the target of interest is specific for human species, e.g. antibody based receptor agonists.
We generally recommend testing of each candidate using human dendritic cells from at least three donors.
Read more about Dendritic Cells in this article from European Biopharmaceutical Review, November 2008 (http://www.bioneer.dk/files/Files/EBR_DC.pdf)
Link to patent information: (http://www.bioneer.dk/index.php?pageid=118)
For further information, please contact Group Leader, Immune Targeting; Simon Skjøde Jensen by phone (+45 45160444) or email: ssj@bioneer.dk
Contact:
| Simon Jensen | Global Leader, Immune Targeting |
Pharmaceutical services, covering the field from lead identification to final formulation of the active compound, are provided by Bioneer:FARMA.
Bioneer:FARMA is a business unit of Bioneer established in collaboration with the Faculty of Pharmaceutical Sciences (FARMA), University of Copenhagen, Denmark .
Bioneer:FARMA can characterize your active compound with regards to physicochemical properties, stability and solid state properties. The permeability of your active compound can be assessed by use of cell culture or excised tissue models. We further evaluate the involvement of active transporters or efflux transporters.
Based on solubility and permeability determinations we classify your compound in the Biopharmaceutics Classification System (BCS).
Bioneer:FARMA can formulate your active compound by utilising both basic and sophisticated formulation technologies, depending on the route of administration and the properties of your active compound. Formulations are characterized and evaluated as described in the European Pharmacopeia and the USP.
Furthermore, Bioneer:FARMA has several physiologically relevant characterization tools available that mainly focused on simulating events and conditions in the gastro-intestinal tract. These tools are able to give an indication of a potential food effect of a given compound and also provide a rational formulation strategy. Developed formulations can be tested in the physiologically relevant models.
Pharmaceutical services for development of both small molecular compounds and biologics (e.g. protein, peptides and oligonucleotides) are available.
Contact:
| Annette Mullertz | Head of Bioneer: FARMA, Bioneer |
Bioneer addresses a client's needs for limited amounts of recombinant proteins, e.g. during the discovery phase and preclinical phase of biologics development.
Different proteins require different production systems, and Bioneer offers to test a client's protein in a variety of microbial and mammalian production systems and, subsequently, to optimise the production system by genetic and physiological means. Specifically, Bioneer offers access to a proprietary microbial production system (P170) through licensing of intellectual property covering the expression system (promoter, signal sequence and an optimised host cell) as well as fermentation technology.
Bioneer has downstream processing capability at gram scale and offers purification of proteins, DNA, RNA and other compounds.
Finally, Bioneer offers small-scale contract production of recombinant proteins compliant with Good Manufacturing Practise.
Contact:
| Soren Madsen | Global Leader, Bacterial Expression |
| Niels Skjærbæk | Business Development Manager |
Bioneer A/S is an innovative research-based CRO company, providing services within biomedicine and biotechnology.
Our commercial mission is to increase the competitiveness of our global customers by facilitating their early, explorative development of new therapeutics. We therefore offer access to essential tools, technology and unique biological resources within cell and molecular biology, and we further aim to create new product opportunities at the interface between biology and other sciences.
Bioneer A/S has 4 major areas of interest:
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
